Status:

COMPLETED

Effects of Enzyme Replacement in Gaucher's Disease

Lead Sponsor:

National Institute of Neurological Disorders and Stroke (NINDS)

Conditions:

Gaucher's Disease

Eligibility:

All Genders

Brief Summary

Gaucher disease is a lysosomal storage disease resulting from glycocerebroside accumulation in macrophages due to a genetic deficiency of the enzyme glucocerebrosidase. It may occur in adults but occu...

Detailed Description

The purpose of this study is to examine the effects of enzyme replacement therapy in patients with neuronopathic Gaucher's disease and to investigate the pathogenesis of their neurological signs and s...

Eligibility Criteria

  • INCLUSION CRITERIA:

    1. All patients with neuropathic Gaucher's disease who have a partial or complete horizontal supranuclear gaze palsy or a genotype associated with neurological involvement.
    2. All candidates must be serologically nonreactive for hepatitis B and human immunodeficiency (AIDS) virus. HIV positive patients will be excluded because of the effects of the latter illness on cognitive performance.
    3. Individuals with neoplastic disease will be excluded.
    4. The general health and well being of each candidate must be sufficient to allow for a modest amount of blood drawing, collection of appropriate urine and spinal fluid specimens and performance of necessary roentgenographic and magnetic resonance (MR) imaging studies. In addition, each candidate must be able to return to the National Institutes of Health (NIH) on a regular basis dictated by disease severity for monitoring of laboratory parameters.

EXCLUSION CRITERIA:

  1. Patient who participates in a clinical study of an investigational therapeutic agent for Gaucher Disease.
  2. Patient and/or the patient's parent(s) or legal guardian(s) are unable to understand the nature, scope, and possible consequences of the study.
  3. Patient is unable to comply with the protocol, e.g., uncooperative with protocol schedule, refusal to agree to all of the study procedures.

Key Trial Info

Start Date :

September 23 1991

Trial Type :

OBSERVATIONAL

End Date :

March 3 2008

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT00001289

Start Date

September 23 1991

End Date

March 3 2008

Last Update

July 2 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States, 20892